Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06133439
Other study ID # 15956
Secondary ID R01CA276659
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 3, 2023
Est. completion date December 2027

Study information

Verified date February 2024
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this implementation study is to support an evidence-based intervention to the improve colorectal cancer (CRC) screening and diagnostic colonoscopy rates in rural Indiana. The main questions the study aims to answer are: - How does the implementation of an evidence based intervention to increase CRC screening in rural Indiana improve CRC screening and diagnostic colonoscopy rates, defined as completed screening episode? - Will dose and type of implementation strategies contribute to differences in contextual factors and readiness as well as different levels of implementation outcomes (reach and implementation) in rural clinic? - Will Contextual factors (innovation, recipient, inner and outer context) and implementation outcomes (reach, and implementation) vary with the levels of CRC screening and diagnostic colonoscopy following active implementation (effectiveness) and throughout maintenance compared to baseline (usual care)? - What is the cost and budget impact of the deployment of implementation strategies and processes for rural clinics and evaluate the cost-effectiveness of implementing and sustaining the CRC screening intervention? Approach: Participating clinics tasks consist of mailing FIT kits, sending text messages, phone reminders, and the use of a Patient Navigator to initiate a screening episode with eligible patients who are 45-75 (and have no colonoscopy in the last 10 years or FIT in the last 12 months) as identified from medical records.


Description:

In Aim 1, the investigators will evaluate the ability of an implementation of an EBI to improve CRC screening and diagnostic colonoscopy rates, defined as completed screening episode (effectiveness) through implementation of an EBI for CRC screening in rural Indiana. The investigators hypothesize that a complete screening episode of CRC screening (FIT or screening colonoscopy), including diagnostic colonoscopy uptake following positive FIT, will be higher following implementation of an EBI and throughout maintenance compared to baseline (usual care). Resolution with diagnostic colonoscopy and repeat screening with FIT will be handled as exploratory outcomes. In Aim 2, the investigators will evaluate the variation in contextual factors (innovation, recipient, inner and outer context), implementation strategies and implementation outcomes (reach and implementation) using mixed data (qualitative interviews and quantitative measures) to build implementation profiles of nine rural clinics. In Aim 3, the investigators estimate the cost and budget impact of the deployment of implementation strategies and processes for rural clinics and evaluate the cost-effectiveness of implementing and sustaining the CRC screening intervention. Study Overview: The investigators will partner with the IRHA, a not-for-profit organization, that was founded in 1997 to meet the healthcare needs of rural residents including Medicare and Medicaid recipients in underserved areas in Indiana. Nine IRHA with CRC screening rates below the state average of 68% were selected. Approach and Design: The EBI for CRC screening consists of mailing an opportunity for patients not up to date with CRC screening to obtain a colonoscopy, Cologuard or FIT kit. Patients are provided with an opportunity to talk to a patient navigator and select screening options. Risk status for colorectal cancer is assessed. To initiate a screening episode, screening eligible patients who are 45-75 (no colonoscopy in the last 10 years or FIT in the last 12 months) will be identified from medical records A centralized PN will serve all clinics during implementation, but this role will transition to clinic staff during maintenance. The PN will provide support to patients making decisions about the correct CRC screening test, scheduling a screening colonoscopy, and follow-up with a diagnostic colonoscopy when an FIT is positive.43,57-71 A standard operating procedure (SOP) will be developed during planning to support the navigation protocol and the transition of the PN role to clinic staff during maintenance. Navigation may include further assessment or confirmation of risk status, discussion about CRC screening or scheduling of a screening colonoscopy. With verbal consent, all calls will be recorded. Using the SOP, clinic staff who have basic medical assistant training will be able to support navigation when the PN role is transitioned to the clinic. A fidelity checklist will be used to assess 25% of all recorded calls for consistency in delivering the navigation protocol. A positive stool-based test will prompt a stepped approach to counseling for diagnostic colonoscopy. Implementation Strategy: The implementation strategy includes four components: 1) external facilitation, 2) CC identification and preparation, 3) establishment of a collaborative learning environment and 4) promotion of local adaptation. Implementation Process: Startup activities occur in Year 1 and include ordering materials and supplies, hiring and training staff, establishing monthly research team meetings and EAB meetings, refining data collection measures and meeting with consultants. Using input from clinic staff, the investigators will hire and train interviewers and establish processes for all data collection including computer interfaces and database management. A PN will be available in each clinic to counsel patients. During Phase 1, investigators will assess CRC screening rates and promotion/education activities to identify a baseline as well as determine costs associated with any currently implemented strategies. Phase 2 begins as each cluster is stepped into the implementation design. A CC will be selected at each clinic and a learning collective will be developed to inform and engage all clinic staff. Before developing a clinic-specific plan, the investigators will assess contextual factors by collecting data from clinic staff and patients to inform the implementation plan. Assessment of contextual factors will provide information about the evidence surrounding the EBI, motivation or self-efficacy of staff/patients for implementing the EBI and factors in the inner or outer context that would facilitate or present challenges to implementation. Following assessment, the clinics will begin development of a plan to support the steps necessary to implement the EBI, including the need for resources such as technical support for EMR programming and development of computerized logs for use in tracking activities. The clinic-specific plan will be developed in partnership with the CC and clinic staff. The learning collaborative will inform the implementation plan development, educate staff about the implementation process, and identify areas where adaptations to the plan are needed. After planning, the clinics will execute the implementation plan. Computerized clinic logs will track all steps of implementing the intervention including FIT and Cologuard distribution and retrieval, scheduling, completion of colonoscopy (screening and diagnostic) and PN calls. During active implementation, both the EIS and CC will use tracking sheets to record all actions, and fidelity will be monitored monthly. Adaptations to the initial implementation plan will be carefully documented. Phase 3 (Maintenance) follows active implementation and is used to monitor continued adoption of the EBI and subsequent CRC screening, including annual repeat FIT screening for those who completed an initial negative FIT and diagnostic colonoscopy following a positive FIT. Cost effectiveness of implementation will be measured.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 11
Est. completion date December 2027
Est. primary completion date December 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - All participants will be staff employed at the respective clinics. Patients will be age 45 to 75 and either male or female. Age limitations are necessary because colorectal cancer screening doesn't start until 45 and ends at 75. Exclusion Criteria: - Under surveillance (inherited familial syndromes),history of inflammatory bowel disease, and a previous adenomatous polyp, or previous colorectal cancer.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Colorectal Screen rates with implementation of evidence-based intervention
Mailed FIT kits, Cologuard, and diagnostic colonoscopies.

Locations

Country Name City State
United States Monroe Family Medicine (Adams Medical Group Monroe) Monroe Indiana

Sponsors (3)

Lead Sponsor Collaborator
Indiana University Indiana University Melvin and Bren Simon Cancer Center, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Maintenance Maintenance will be assessed by interviewing clinic staff to determine if the EBI will be maintained, barriers and facilitators to EBI use, and adaptations made to the implementation process. Up to 36 month
Primary Effectiveness and Maintenance The primary effectiveness measure will be the rate of uptake of a complete episode CRC screening, a rate that includes resolution of a positive FIT test with diagnostic colonoscopy. Up to 12 months
Primary Contextual factors Contextual factors will be measured at the beginning of Phase 2 and during the midpoint and end of Phase 3. Semi structured items are used for contextual factors and are guided by the iPARIHS framework. The final contextual factor construct assessed during the interview will be readiness to engage in implementation of the EBI, measured by the Organizational Readiness to Change Assessment (ORCA). Up to 12 months
Primary Implementation outcomes Measured by CC tracking forms, clinic logs that record all PN calls, adaptations to the implementation plan, fidelity measures and costs. The Clinic Implementation Tracking Form contains all essential tasks in the implementation plan including the dose and quality of intervention delivery. Overall quality of implementation and responsiveness to facilitation will be rated on a scale of 1 to 3. At the end of Phase 3, the investigators will interview two staff/clinic about their perceptions of the implementation. The investigators will also measure responses to a validated Acceptability scale using two staff/clinic at each clinic. All adaptations to the implementation plan will be recorded including rationale for change. Cost-data will be collected in phase 1 for usual care CRC screening promotion/education activities and throughout Phase 2 and 3 of implementation. Up to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A